Key result
Peptide scanning identified antigenic sites in the VP0 polypeptide and the C-terminal region of VP1 containing an RGD motif that elicited neutralizing activity against human parechovirus 1.
Population
Rabbit and murine HPEV1 antisera, and HPEV1 clinical isolates from Finland and the United States
Design
Preclinical
Authors
Loading...
Epitopes may guide HPEV1 vaccine design; leaves open human translation from animal data.
Identified specific antigenic sites in HPEV1 capsid proteins that elicit neutralizing antibodies, providing insights into the virus's immunological characteristics.
Joki‐Korpela et al. (2000) studied Human parechovirus 1. Peptide scanning and antiserum testing was evaluated on Identification of immunogenic peptide sequences and neutralizing activity. Peptide scanning identified antigenic sites in the VP0 polypeptide and the C-terminal region of VP1 containing an RGD motif that elicited neutralizing activity against human parechovirus 1.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: